Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038714
Status:
COMPLETED
Last Update Posted:
2007-06-27
First Post:
2002-06-04
Brief Title:
A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis
Sponsor:
Nventa Biopharmaceuticals Corporation
Organization:
Nventa Biopharmaceuticals Corporation
Study Overview
Official Title:
A Phase II Trial of SGN-00101 In The Treatment of Pediatric Recurrent Respiratory Papillomatosis
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Recurrent Respiratory Papillomatosis RRP causes wart-like lesions along the throat area and can obstruct the airway or become malignant The cause has been related to specific types of Human Papillomavirus HPV The purpose of the study is to assess the clinical effectiveness of a trial drug SGN-00101 in children with RRP and also assess its safety
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SGN-00101-0005 | None | None | None |